Troubled Immunomedics tries again at FDA after rejection

Immunomedics has had a long and troubled road in the past few years that has included losing much of its C-suite after an FDA rejection, not to mention the strange failure of a $2 billion deal with Seattle Genetics.

Now, the biotech is hoping to reset after resubmitting its once-rejected antibody-drug conjugate IMMU-132 (sacituzumab govitecan) to the FDA.